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Adiponectin has anti-atherosclerotic effects through its direct actions on vascular cells. The present
study investigates the molecular mechanisms of adiponectin in the migration of endothelial pro-
genitor cells (EPCs) which play an important role in neovascularization and re-endothelization.
The phosphorylation of Akt and the activations of Cdc42 and Rac1 were signiﬁcantly increased by
adiponectin. Adiponectin increased the migration activity of EPCs, which was completely inhibited
by a PI3-kinase inhibitor. siRNA of Cdc42 or Rac1 completely inhibited the adiponectin-induced
migration, but siRNA of Akt had no effects, indicating that adiponectin promotes the migration
activities of EPCs mainly through PI3-kinase/Cdc42/Rac1.
Structured summary:
MINT-7217629: PAK1 (uniprotkb:Q13153) physically interacts (MI:0914) with CDC42 (uniprotkb:P60953)
by pull down (MI:0096)
MINT-7217644: PAK1 (uniprotkb:Q13153) physically interacts (MI:0914) with Rac1 (uniprotkb:P63000)
by pull down (MI:0096)
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction a chemoattractant for HUVECs in migration and stimulated bloodAdiponectin is an adipocyte-speciﬁc secretory protein that has
been implicated as a mediator of systemic insulin sensitivity with
the liver and muscle as target organs [1–3]. The plasma adiponec-
tin levels, which are decreased in obese patients, animal models of
obesity, coronary artery disease and type 2 diabetes [4–6], corre-
late inversely with insulin resistance [7,8]. Adiponectin has also
been recently revealed to have anti-atherogenic and anti-inﬂam-
matory properties. Overexpression of adiponectin reduces athero-
sclerotic lesions in mouse models, whereas adiponectin-deﬁcient
mice exhibit excessive intimal responses to vascular injury and
diet-induced insulin resistance [9,10]. Moreover, adiponectin was
found to be capable of stimulating angiogenesis [11]. Adiponectin
promoted the formation of capillary-like structures from human
umbilical vein endothelial cells (HUVECs) in vitro, functioned aschemical Societies. Published by E
Endocrinology and Diabetes,
65 Tsuruma-cho, Showa-ku,
.vessel growth in mouse [12].
On the other hand, endothelial progenitor cells (EPCs), which
were ﬁrst identiﬁed in adult peripheral blood mononuclear cells
(MNCs) in 1997 [13], play an important role in postnatal neovascu-
larization. EPCs contribute to the process of vasculogenesis, which
comprises the adhesion of EPCs to the sites of vascularization and
their subsequent inﬁltration and partial digestion of the target tis-
sue resulting in the growth of a new blood vessel [14]. A number of
experimental and clinical studies have revealed that transplanta-
tion of EPCs is an effective treatment for ischemic heart disease
and arteriosclerosis obliterans because of the resulting neovascu-
larization [15,16]. We revealed that transplantation of EPCs ame-
liorated diabetic neuropathy by increasing the tissue blood ﬂow
[17]. Many successful outcomes of experimental and clinical stud-
ies suggest that EPCs have a stronger potential for neovasculariza-
tion than mature endothelial cells.
The mobilization and differentiation of EPCs were shown to be
important in the process of adult neovascularization [18]. EPCs,
cooperating with local endothelial cells, play a role in the formationlsevier B.V. All rights reserved.
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the number andmigratory activity of circulating EPCs inversely cor-
relate with risk factors for coronary artery disease, suggesting that
EPCs could serve as a surrogate biological marker for vascular func-
tion and cumulative cardiovascular risk [19]. Furthermore, de-
creased numbers and functional deﬁcits of EPCs were observed in
types 1 and 2 diabetic patients [20,21], and the recruitment of EPCs
into the aorta is decreased in diabetic animals. These results suggest
that such deﬁcits in the number and function of EPCs may contrib-
ute to the macrovascular complications in diabetic patients.
Although adiponectin is reported to increase the numbers and
migration of EPCs [22,23], the precise mechanisms are still obscure.
In this study,we have identiﬁed that adiponectin induces themigra-
tion of EPCs via the PI3-kinase/Cdc42/Rac1 pathway. Our ﬁndings
reveal not only the role of adiponectin in neovasculogenesis and
vascular repair, but also the therapeutic potency of adiponectin.2. Materials and methods
2.1. Human umbilical cord blood
Human umbilical cord blood (50–120 ml) was obtained from
each donor after childbirth. Written informed consent was ob-
tained from all mothers before labor and delivery. Protocols for
sampling human umbilical cord blood were approved by the Insti-
tutional Review Board.
2.2. Puriﬁcation and cell culture of EPCs
EPCs were isolated from human cord blood using a Histopaque-
density centrifugation method previously described [17]. Non-
adherent cells were discarded after 48 h incubation. For the
identiﬁcation of EPCs, FACS analyses of freshly isolated cells
were performed after 7 days in culture. Cells were ﬁxed with 1%
paraformaldehyde and labeled with phycoerythrin-conjugated
CD31 (clone WN59; BD Biosciences, San Jose, CA); CD34 (clone
8G12; BD Biosciences, San Jose, CA); KDR (clone 89106; TECUNE
Corporation, Minneapolis, MN) and Tie-2 (clone 83715; R&D
Systems, Minneapolis, MN). Isotype-identical antibodies served
as controls.
2.3. Identiﬁcation of adiponectin receptor
The adiponectin receptor was identiﬁed by Western blot analy-
ses using anti-human AdipoR1 antibody and anti-mouse AdipoR2
antibody (Alexis Biochemicals, San Diego, CA).
2.4. RNA interference
The siRNA-mediated knockdown of Akt, Cdc42 and Rac1 was
performed using previously described methods [24]. The targeted
sequences that effectively mediated the silencing of the expression
of Akt, Cdc42 and Rac1 were prepared by Qiagen (Hilden, Ger-
many). EPCs were transfected with the siRNAs or a 21-nucleotide
irrelevant RNA (Qiagen) as a control, by using RNAifect (Qiagen)
according to the manufacturer’s protocol.
2.5. Western blot analyses
Conﬂuent-grown EPCs were stimulated with 5 lg/ml full-
length adiponectin (Biovender; Candler, NC) for the indicated peri-
ods. A sample (20 lg) of lysate protein was subjected to SDS–PAGE
and detected by the ﬁrst antibodies of anti-phospho-Akt (Ser473),
anti-Akt, anti-phospho-ERK (Thr202/Tyr204) and anti-ERK (Cell
Signaling Technology Inc., Beverly, MA).2.6. Cdc42/Rac1 activity assay
To investigate whether adiponectin activates Cdc42 and Rac1,
we used a Cdc42/Rac1 activation assay kit (from Cytoskeleton)
according to the instructions provided by the manufacturer. This
is a direct pull-down experiment performed by measuring the
binding capability of GTP-bound Cdc42 or Rac1 to GSTPAK1 PBD
fusion protein immobilized onto glutathione agarose beads. The
amounts of active Cdc42 and Rac1 were measured by Western blot
analyses.
2.7. Migration assay
To assess the migration of EPCs, we performed a modiﬁed Boy-
den chamber migration assay. The chambers were placed in 24-
well dishes ﬁlled with M199 containing 0.1% BSA with adiponectin
(5–10 lg/ml) or VEGF (10–20 ng/ml) added to the lower chamber,
and the chambers were incubated for 12 h. After incubation, cells
were labeled with Hoechist 33342. The adiponectin-stimulated
migratory capacity was then quantiﬁed by counting the migrated
EPCs on the lower surface of the ﬁlter using ﬂuorescence
microscopy.
2.8. Immunoﬂuorescent staining of EPCs
Cultured cells were ﬁxed with 4% paraformaldehyde in 0.1 M
PBS, permeabilized with 0.05%-triton X in PBS and stained with
Alexa Fluor 488-conjugated phalloidin (Invitrogen Co., Carlsbad,
CA). Fluorescence was examined using a ﬂuorescent microscope
(BX51, Olympus, Tokyo, Japan).
2.9. Statistical analysis
All the group values were expressed as means ± S.E. Statistical
analyses were assessed by one-way ANOVA. The level of signiﬁ-
cance was set at P < 0.05.3. Results
3.1. Identiﬁcation of EPCs
EPCs, isolated from the culture of cord blood-derived mononu-
clear cells, expanded from the attached cells (Fig. 1A). A linear for-
mation was occasionally observed during the expansion of EPCs
(Fig. 1B). More than 90% of the isolated cells were identiﬁed by
DiI-acetylated LDL, which is a marker of vascular endothelial cells
(Fig. 1C). On the other hand, HUVECs never showed the linear for-
mation (data not shown). Flow cytometric analyses revealed posi-
tive staining with CD34 (81.3%), CD31 (89.4%), KDR (68.2%) and
Tie-2 (78.8%) (Fig. 1D).
3.2. Identiﬁcation of adiponectin receptor
To examine whether EPCs have adiponectin receptors, we eval-
uated the expressions of adiponectin receptors, AdipoR1 and Adi-
poR2 in EPCs using Western blot analyses. AdipoR1 was
identiﬁed as a single band at 40 kDa (Fig. 2A). We also detected a
single band stained with anti-mouse AdipoR2 (Fig. 2B), which
had 93% homology with the human AdipoR1 sequences.
3.3. Adiponectin stimulates the phosphorylation of Akt, but not ERK
Adiponectin signiﬁcantly stimulated the phosphorylation of Akt
in a time-dependent manner (Fig. 3A). The phosphorylation of Akt
was rapidly increased at 10 min after adiponectin stimulation. On
Fig. 1. Culture and identiﬁcation of EPCs from cord blood. (A) EPCs, isolated from the culture of cord blood MNCs, expanded from attached cells. (B) A linear formation is
occasionally observed during the expansion of EPCs. (C) The uptake of DiI-acetylated LDL. (D) Flow cytometric analysis revealed positive staining with CD34, CD31, KDR and
Tie-2.
Fig. 2. Expression of adiponectin receptors, AdipoR1 (A) and AdipoR2 (B), in EPCs. Adiponectin receptors were identiﬁed by Western blot analyses using anti-human AdipoR1
antibody and anti-mouse AdipoR2 antibody.
Fig. 3. The phosphorylations of Akt and ERK stimulated by adiponectin. Adiponectin stimulation (5 lg/ml) was conducted for the indicated time. (A) Adiponectin increased
the phosphorylation of Akt. (B) The phosphorylation of ERK did not change by adiponectin. Results are shown as the means ± S.E. (n = 3) (*P < 0.05, **P < 0.01 vs. 0 min). One
out of three experiments with similar results is shown. (C) The phosphorylation of Akt was inhibited by LY294002.
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of ERK (Fig. 3B). To assess whether adiponectin-stimulated Akt
phosphorylation via PI3-kinase (PI3K), we measured the effect of
LY294002, a PI3K inhibitor, on the phosphorylation of Akt. The
phosphorylation of Akt was completely inhibited by LY294002
(Fig. 3C).3.4. Adiponectin stimulates the activities of Cdc42 and Rac1
As shown in Fig. 4, both Cdc42 and Rac1 were activated by
adiponectin stimulation. Maximum Cdc42 and Rac1 activation oc-
curred at 2 min after adiponectin stimulation (Fig.4A and B). Next,
we measured the effect of LY294002 on the activation of Cdc42 and
2460 N. Nakamura et al. / FEBS Letters 583 (2009) 2457–2463Rac1. Both Cdc42 and Rac1 were inhibited by LY294002, indicating
that adiponectin-stimulated Cdc42 and Rac1 via PI3K (Fig. 4C).
3.5. Adiponectin promotes migration activity of EPCs via PI3K/Cdc42/
Rac1
The number of migrated cells attracted by adiponectin was
about seven times greater than that under the serum-free condi-
tion (Fig. 5A). The migratory activities of EPCs were increased in
a dose-dependent manner by adiponectin as well as by VEGF.
The adiponectin-induced enhancement of migratory activities
was completely inhibited by LY294002 (91.7% suppression)
(Fig. 5B). On the other hand, the MEK inhibitor, PD98059 did not
inhibit the adiponectin-induced EPC migration, suggesting that
an ERK-dependent pathway is not involved in the migratory effect
of adiponectin in EPCs.
To elucidate the signaling pathway of adiponectin-stimulated
migration, targeted knockdown using siRNA was performed. Wes-
tern blot analyses showed that transfection with the Cdc42, Rac1
and Akt siRNAs effectively reduced the expression levels by over
90% (Fig. 6A). As shown in Fig. 6B, the adiponectin-induced migra-
tory activities were completely inhibited by siRNA of Cdc42 and
Rac1 (85.7% suppression by Cdc42-siRNA and 88.5% suppression
by Rac1-siRNA). However, siRNA of Akt had no effect on the adipo-
nectin-stimulated migration (1.4% suppression). These observa-
tions suggest that adiponectin stimulates Akt, Cdc42 and Rac1
via PI3K, but the migratory effects of adiponectin on EPCs mainly
act through PI3K/Cdc42/Rac1 (Fig. 7).
3.6. Adiponectin promotes actin organization of EPCs via Rac1
The actin structure was visualized by staining EPCs with Alexa
Fluor 488-conjugated phalloidin, which probes ﬁlamentous actin.Fig. 4. The activations of Cdc42 and Rac1 stimulated by adiponectin. Adiponectin stimul
Rac1 were detected by pull-down assay. (A) Adiponectin stimulated the activation of C
means ± S.E. (n = 3) (*P < 0.05, **P < 0.01 vs. 0 min). One out of three experiments with s
Fig. 5. Migration of EPCs stimulated by adiponectin. (A) Modiﬁed Boyden chamber ass
induced enhancement of migration activities was inhibited completely by LY294002, buEPCs without stimulation did not form clear actin organization
(Fig. 8A). Adiponectin induced actin organization and lamellipodia
formation at the cortex of EPCs (Fig. 8B). Rac1-siRNA blocked
adiponectin-induced actin organization and lamellipodia forma-
tion in EPCs (Fig. 8C). On the other hand, Akt-siRNA did not effect
adiponectin-induced actin polymerization and lamellipodia forma-
tion in EPCs (Fig. 8D).
4. Discussion
EPCs contribute to the process of vasculogenesis, which com-
prises the adhesion of EPCs to the sites of vascularization and their
subsequent inﬁltration and partial digestion of the target tissue,
resulting in the growth of a new blood vessel. In the present study,
we have reported, for the ﬁrst time, that adiponectin at its physio-
logical plasma concentration could promote EPC migration
through PI3K/Cdc42/Rac1.
Many successful outcomes of experimental and clinical studies
suggest that EPCs have a stronger potential for neovascularization
than ECs. We reported that transplantation of EPCs ameliorated
diabetic neuropathy by increasing the tissue blood ﬂow [17]. En-
hanced cell migration is one of the underlying mechanisms in angi-
ogenesis of EPCs. Therefore, inducing EPCs migration is considered
to be a potentially effective strategy for angiogenesis. On the other
hand, decreased numbers and functional deﬁcits of EPCs in diabetic
patients have been reported. In both types 1 and 2 diabetic pa-
tients, the numbers of EPCs were signiﬁcantly decreased compared
with normal subjects, and this was inversely correlated with
HbA1c [20,21]. Tube formation of EPCs was also decreased in types
1 and 2 diabetic patients. In vitro experiments revealed that high
glucose decreased the proliferation of EPCs [25]. These results sug-
gest that the impaired function of EPCs may contribute to the dia-
betic macroangiopathy.ation (5 lg/ml) was conducted for the indicated time. The activations of Cdc42 and
dc42. (B) Adiponectin stimulated the activation of Rac1. Results are shown as the
imilar results is shown. (C) Both Cdc42 and Rac1 were inhibited by LY294002.
ay was performed with adiponectin or VEGF as chemoattractant. (B) Adiponectin-
t not by PD98059 (*P < 0.05, vs. serum free control).
Fig. 6. The effects of Akt, Cdc42 and Rac1 on adiponectin-induced migration of EPCs. (A) The siRNA-mediated knockdown of Akt, Cdc42 and Rac1. (B) Adiponectin-induced
migration activities were completely inhibited by siRNA of Cdc42 and Rac1 (85.7% suppression by Cdc42-siRNA and 88.5% suppression by Rac1-siRNA). However, the
migration activity was not inhibited by a siRNA of Akt (1.4% suppression). Results are shown as the means ± S.E. (n = 3).
Fig. 7. Proposed scheme for adiponectin-stimulated signaling in the migration of
EPCs.
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sis. Adiponectin also potently increased both the EPC numbers and
migration capability [22,23]. Another report revealed that adipo-
nectin knockout mice had a primary state of endothelial dysfunc-
tion with increased leukocyte–endothelium adhesiveness [26].
The present study conﬁrmed the promotion of the migration of
EPCs by adiponectin. PI3K, which is upstream of Akt and Cdc42,
is one of the most important regulatory proteins involved in con-
trolling several key functions of the cell, such as cell growth, aging,
and transformation [27,28]. It was demonstrated in this study that
adiponectin caused a dose-dependent migration of EPCs. This
adiponectin-mediated migration was markedly suppressed by the
administration of a PI3K inhibitor, LY294002. These results indi-
cate that the effect of adiponectin on the EPC function was medi-
ated in a PI3K-dependent manner.
Akt is an important regulator of various cellular processes
including glucose metabolism and cell survival. Akt has been re-
ported to directly activate eNOS, suggesting that Akt may regulate
the increased production of nitric oxide in response to adiponectin
stimulation [29,30]. Adiponectin has recently been revealed to
stimulate the PI3K/Akt signaling pathway to enhance EC prolifera-
tion and migration [12]. However, in this study, we found that the
activation of Akt was not essential for the adiponectin-inducedmigration of EPCs. Conﬂicting reports exist as to the role of Akt
in cell migration. Several studies have demonstrated that Akt plays
a positive role in migration, whereas other studies have reported
conﬂicting results [31–33]. The discrepancy in the results, obtained
in response to different stimulators, could be due to the activation
of different signaling pathways in the different cell types.
The Rho family GTPases play critical roles in various situations
such as cell growth, metastasis, morphogenesis, organogenesis
and pathogenesis [34]. Cdc42 and Rac1 were reported to act as
downstream effectors of PI3K in several growth factor-stimulated
pathways [35,36]. We have discovered that Cdc42 and Rac1 were
essential downstream proteins in EPC migration. Migrating cells
cause a special actin organization, called ‘‘lamellipodium”, at the
leading edge of migration [37]. We have shown that adiponectin
stimulates the lamellipodium formation at the cortex of EPC, which
is suppressed by the inhibition of Rac1. These data suggest that the
pro-angiogenic effects of the adiponectin-stimulated PI3K activity
are due in large part to an activation of Cdc42/Rac1.
On the other hand, adiponectin did not affect the phosphoryla-
tion of ERK1/2. We also observed that the MEK inhibitor, PD98059,
did not inhibit the adiponectin-induced EPC migration suggesting
that none of those kinase-dependent pathways is involved in the
migratory effect of adiponectin. Our data are consistent with a pre-
vious report that adiponectin affected no phosphorylation of ERK
induced by TNF-a in HAEC.
Adiponectin in the circulation forms a complex of a trimer
(high molecular weight form). We used the full-length adiponectin
comprised of both the high and low molecular weight forms. We
found that EPCs have both adiponectin receptor types 1 and 2 (Adi-
poR1 and R2). These results provide important insights into the
molecular mechanisms underlying the promotion of EPC migration
by adiponectin. However, we were not able to elucidate whether it
was adiponectin receptor R1 or R2 that contributes to the EPC
migration induced by adiponectin. Further study is being con-
ducted in our laboratory to answer this question.
In conclusion, we revealed that adiponectin at the physiological
plasma concentration can promote the migration of EPCs, mainly
through PI3K/Cdc42/Rac1. Our present study provides important
insights into the molecular mechanisms underlying EPC migration.
Taken together, these results suggest that exogenous supplemen-
tation of adiponectin could be useful for therapeutic angiogenesis
in patients who suffer from vascular complications such as ische-
mic heart disease and diabetes. This study may provide a better
Fig. 8. The actin structure was visualized with the staining of the cells with Alexa Fluor 488-conjugated phalloidin. (A) The ﬁlamentous actin in EPC without stimulation. (B)
The actin organization and lamellipodium formation at the cortex of EPC under adiponectin stimulation. (C) Rac1-siRNA blocked adiponectin-induced actin organization and
lamellipodia formation in EPC. (D) Akt-siRNA did not effect the adiponectin-induced actin organization and lamellipodia formation in EPCs (scale-bar = 20 lm).
2462 N. Nakamura et al. / FEBS Letters 583 (2009) 2457–2463understanding of the biological functions of adiponectin and its po-
tential clinical applications.
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